A Study of Evacetrapib and Rifampin in Healthy Participants
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine how much evacetrapib gets into the blood
stream and how long it takes the body to get rid of it when given with rifampin. The safety
and tolerability of the two drugs, given together, will also be evaluated. The study will
also look at blood cholesterol levels and levels of a hormone called cortisol before and
after taking rifampin. Information about any side effects that may occur will also be
collected.
For each participant, this study will include 2 periods in fixed order. The study will last
approximately 29 days.